Guidant admits DES (drug-eluting stent) trial setback, buys Biosensors assets
This article was originally published in Clinica
Executive Summary
An unexpectedly high foreign body response in animal studies is the latest setback to Guidant in its struggle to bring a drug-eluting stent to market.